TD Cowen lowered the firm’s price target on Alignment Healthcare to $10 from $17 and keeps an Outperform rating on the shares. The analyst said its revenue and EBITDA results beat 4Q consensus although the composition of MLR miss/G&A beat is less desirable.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ALHC:
- CORRECTION — Alignment Healthcare Reports Fourth Quarter and Full-Year 2022 Results; Provides Full-Year 2023 Financial Guidance
- Alignment Healthcare sees Q1 revenue $429M- $434M, consensus $420.54M
- Alignment Healthcare reports Q4 EPS 31c, consensus 30c
- Alignment Healthcare Reports Fourth Quarter and Full-Year 2022 Results; Provides Full-Year 2023 Financial Guidance
- Alignment Healthcare downgraded to Neutral from Overweight at JPMorgan